Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov062013	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013 SAN DIEGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2013 Financial Results on November 13, 2013 10 KB
Toggle SummaryNov132013	Fate Therapeutics Reports Third Quarter 2013 Financial Results Cleared Key Milestones for Resumption of ProHema Phase 2 Clinical Trial Selected Wnt7a Protein Analogs for Advancement into IND-Enabling Activities Extended Breadth of Patent Protection for HSC Modulation Platform SAN DIEGO, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2013 Financial Results 28.6 KB
Toggle SummaryFeb262014	Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R) SAN DIEGO, Feb. 26, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic Read All »	View HTML Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R) 17.8 KB
Toggle SummaryFeb272014	Fate Therapeutics to Present at Upcoming March Conferences SAN DIEGO , Feb. 27, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer , M.D., M.A.S., President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Upcoming March Conferences 17.2 KB
Toggle SummaryFeb282014	Fate Therapeutics Observes Rare Disease Day 2014 SAN DIEGO, Feb. 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy organizations Read All »	View HTML Fate Therapeutics Observes Rare Disease Day 2014 14.2 KB
Toggle SummaryMar062014	Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics SAN DIEGO, March 6, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate Read All »	View HTML Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics 15.1 KB
Toggle SummaryMar112014	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014 SAN DIEGO , March 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014 16.6 KB
Toggle SummaryMar122014	Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies First Patient Enrolled in PUMA Study Approved for Conduct at Ten Leading U.S. Centers Interim Data Expected in 2H14 SAN DIEGO, March 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators Read All »	View HTML Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies 18.6 KB
Toggle SummaryMar172014	Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors. Dr. Read All »	View HTML Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors 84.4 KB
Toggle SummaryMar172014	Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results Phase 2 PUMA Study of PROHEMA® Initiated - Interim Data Expected in 2H14 Clinical Trial of PROHEMA ® in Lysosomal Storage Disorders to Begin in 2H14 Encouraging Clinical Data Published Highlighting the Potential of Ex Vivo T Cell Modulation SAN DIEGO, March 17, 2014 (GLOBE NEWSWIRE) -- Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results 84.4 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.